Sensus Healthcare (NASDAQ:SRTS) Posts Earnings Results, Misses Estimates By $0.03 EPS

Sensus Healthcare (NASDAQ:SRTS) issued its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), FiscalAI reports. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The business had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $6.61 million.

Sensus Healthcare Stock Down 5.6%

NASDAQ SRTS traded down $0.19 on Thursday, reaching $3.22. The stock had a trading volume of 82,587 shares, compared to its average volume of 104,935. The stock has a fifty day moving average price of $3.00 and a two-hundred day moving average price of $3.47. Sensus Healthcare has a 12-month low of $2.66 and a 12-month high of $5.49. The firm has a market capitalization of $53.00 million, a price-to-earnings ratio of -3.43 and a beta of 1.18.

Insider Activity

In other news, Director Eric Sachetta acquired 37,537 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, with a total value of $129,127.28. Following the transaction, the director owned 267,480 shares in the company, valued at approximately $920,131.20. This trade represents a 16.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders bought 120,171 shares of company stock valued at $405,230. Company insiders own 10.20% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SRTS. Lake Street Capital dropped their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensus Healthcare has an average rating of “Moderate Buy” and an average target price of $5.83.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin. Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.